Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT

Study information

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-1

study design

time series / longitudinal observational

Citation

PMID PubMed identifier for scientific articles.

25893458

DOI Digital object identifier for electronic documents.

10.1038/bmt.2015.16

URI

Authors

Biagi E, Zama D, Nastasi C, Consolandi C, Fiori J, Rampelli S, Turroni S, Centanni M, Severgnini M, Peano C, de Bellis G, Basaglia G, Gotti R, Masetti R, Pession A, Brigidi P, Candela M

Journal

Bone marrow transplantation

Year

2015

Acute GvHD (aGvHD) is the main complication of hematopoietic SCT (HSCT) during the treatment of hematological disorders. We carried out the first longitudinal study to follow the gut microbiota trajectory, from both the phylogenetic and functional points of view, in pediatric patients undergoing HSCT. Gut microbiota trajectories and short-chain fatty acid production profiles were followed starting from before HSCT and through the 3-4 months after transplant in children developing and not developing aGvHD. According to our findings, HSCT procedures temporarily cause a structural and functional disruption of the gut microbial ecosystem, describing a trajectory of recovery during the following 100 days. The onset of aGvHD is associated with specific gut microbiota signatures both along the course of gut microbiota reconstruction immediately after transplant and, most interestingly, prior to HSCT. Indeed, in pre-HSCT samples, non-aGvHD patients showed higher abundances of propionate-producing Bacteroidetes, highly adaptable microbiome mutualists that showed to persist during the HSCT-induced ecosystem disruption. Our data indicate that structure and temporal dynamics of the gut microbial ecosystem can be a relevant factor for the success of HSCT and opens the perspective to the manipulation of the pre-HSCT gut microbiota configuration to favor mutualistic persisters with immunomodulatory properties in the gut.

Experiment 1

Edit History Delete

Flag for review

Your review change was submittedDuplicate this Experiment Add a new Signature

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-1

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): WikiWorks, Chloe, ChiomaBlessing, Ifeanyisam

Subjects

Location of subjects: Italy

Host species Species from which microbiome was sampled. Contact us to have more species added.: Homo sapiens

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology: Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology: Graft versus host disease disease, graft-versus-host,disease, graft-VS-host,disease, homologous wasting,disease, runt,diseases, graft-versus-host,diseases, graft-VS-host,graft versus host disease,graft VS host disease,graft VS. host disease,graft-versus-host disease,graft-versus-host disease, resistance to,graft-versus-host disease, susceptibility to,graft-versus-host diseases,graft-versus-host-disease,graft-VS-host disease,graft-VS-host diseases,GVH,GVHD,GVHDS,homologous wasting disease,runt disease,Graft versus host disease

Group 0 name Corresponds to the control (unexposed) group for case-control studies: non-GvHD (Graft-versus-host disease)

Group 1 name Corresponds to the case (exposed) group for case-control studies: aGvHD (acute Graft-versus-host disease)

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: pre-HSCT (hematopoietic stem cell transplant) samples of subjects who underwent HSCT who developed acute graft-versus-host disease

Group 0 sample size Number of subjects in the control (unexposed) group: 5

Group 1 sample size Number of subjects in the case (exposed) group: 5

Lab analysis

Sequencing type: 16S

16S variable region One or more hypervariable region(s) of the bacterial 16S gene: V4

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance: Roche454

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).: relative abundances

Statistical test: Mann-Whitney (Wilcoxon)

Significance threshold p-value or FDR threshold used for differential abundance testing (if any): 0.05

MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?: Yes

Signature 1

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-1

Curated date: 2021/01/10

Curator: William Lam

Revision editor(s): WikiWorks, Chloe, ChiomaBlessing

Source: Results (Text): Page 4, 3rd paragraph under sub-heading "aGvHD-associated gut microbiota signatures."

Description: Gut microbiota signatures in pre-HSCT samples of subjects who developed aGvHD compared to subjects who did not develop aGvHD (non-aGvHD)

Abundance in Group 1: decreased abundance in aGvHD (acute Graft-versus-host disease)

NCBI	Quality Control	Links
Bacteroidia

Revision editor(s): WikiWorks, Chloe, ChiomaBlessing

Signature 2

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-1

Curated date: 2024/02/01

Curator: ChiomaBlessing

Revision editor(s): ChiomaBlessing, WikiWorks

Source: Results (Text): Page 4, 3rd paragraph under sub-heading "aGvHD-associated gut microbiota signatures."

Description: Gut microbiota signatures in pre-HSCT samples of subjects who developed aGvHD compared to subjects who did not develop aGvHD (non-aGvHD)

Abundance in Group 1: increased abundance in aGvHD (acute Graft-versus-host disease)

NCBI	Quality Control	Links
Bacillota

Revision editor(s): ChiomaBlessing, WikiWorks